Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury

Abdelrahman Y. Fouda, Bindu Pillai, Krishnan M. Dhandapani, Adviye Ergul, Susan C. Fagan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Introduction We and others have shown that the angiotensin type 2 (AT2) receptor agonist, compound 21 (C21), provides neuroprotection and enhances recovery in rodent stroke models yet the mechanism involved is not known. Moreover, C21 treatment is associated with an anti-inflammatory response. Here we tested the hypothesis that C21 mediates neuroprotection by upregulating the neuroprotective and anti-inflammatory cytokine, interleukin (IL)−10. Methods Wistar rats were subjected to 3 h-middle cerebral artery suture occlusion and treated at reperfusion with C21 (0.03 mg/kg)±IL-10 neutralizing antibody (0.1 mg/kg) both given i.p. Infarct size, behavioral outcomes, and molecular analysis were performed at 24 h post-injury. Primary rat neurons were used to test the direct neuroprotective effect of C21 in vitro. Results C21 treatment reduced infarct size, improved functional outcome and decreased the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF-α) in the ischemic hemisphere compared to saline. Anti-IL-10 co-treatment blocked the C21-induced reduction in infarct size and inflammation, and the improvement in behavioral outcome. In vitro, C21 treatment increased neuron survival and reduced cell apoptosis after oxygen glucose deprivation (OGD) and OGD/reoxygenation. These effects were mediated through AT2R stimulation. Conclusion C21 provides direct neuroprotection as well as indirect protection through IL-10.

Original languageEnglish (US)
Pages (from-to)128-134
Number of pages7
JournalEuropean Journal of Pharmacology
Volume799
DOIs
StatePublished - Jan 1 2017

Fingerprint

Angiotensin Type 2 Receptor
Neuroprotective Agents
Reperfusion Injury
Interleukin-10
Anti-Inflammatory Agents
Cytokines
Oxygen
Neurons
Glucose
Middle Cerebral Artery Infarction
Neutralizing Antibodies
Sutures
Reperfusion
Wistar Rats
Rodentia
Cell Survival
Tumor Necrosis Factor-alpha
Stroke
Apoptosis
Inflammation

Keywords

  • And Interleukin 10
  • Angiotensin Type 2 Receptor
  • Compound 21
  • Neuroprotection
  • Stroke

ASJC Scopus subject areas

  • Pharmacology

Cite this

Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury. / Fouda, Abdelrahman Y.; Pillai, Bindu; Dhandapani, Krishnan M.; Ergul, Adviye; Fagan, Susan C.

In: European Journal of Pharmacology, Vol. 799, 01.01.2017, p. 128-134.

Research output: Contribution to journalArticle

@article{680a8ad9295a4d679ee062d6b8397e0e,
title = "Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury",
abstract = "Introduction We and others have shown that the angiotensin type 2 (AT2) receptor agonist, compound 21 (C21), provides neuroprotection and enhances recovery in rodent stroke models yet the mechanism involved is not known. Moreover, C21 treatment is associated with an anti-inflammatory response. Here we tested the hypothesis that C21 mediates neuroprotection by upregulating the neuroprotective and anti-inflammatory cytokine, interleukin (IL)−10. Methods Wistar rats were subjected to 3 h-middle cerebral artery suture occlusion and treated at reperfusion with C21 (0.03 mg/kg)±IL-10 neutralizing antibody (0.1 mg/kg) both given i.p. Infarct size, behavioral outcomes, and molecular analysis were performed at 24 h post-injury. Primary rat neurons were used to test the direct neuroprotective effect of C21 in vitro. Results C21 treatment reduced infarct size, improved functional outcome and decreased the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF-α) in the ischemic hemisphere compared to saline. Anti-IL-10 co-treatment blocked the C21-induced reduction in infarct size and inflammation, and the improvement in behavioral outcome. In vitro, C21 treatment increased neuron survival and reduced cell apoptosis after oxygen glucose deprivation (OGD) and OGD/reoxygenation. These effects were mediated through AT2R stimulation. Conclusion C21 provides direct neuroprotection as well as indirect protection through IL-10.",
keywords = "And Interleukin 10, Angiotensin Type 2 Receptor, Compound 21, Neuroprotection, Stroke",
author = "Fouda, {Abdelrahman Y.} and Bindu Pillai and Dhandapani, {Krishnan M.} and Adviye Ergul and Fagan, {Susan C.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.ejphar.2017.02.016",
language = "English (US)",
volume = "799",
pages = "128--134",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury

AU - Fouda, Abdelrahman Y.

AU - Pillai, Bindu

AU - Dhandapani, Krishnan M.

AU - Ergul, Adviye

AU - Fagan, Susan C.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction We and others have shown that the angiotensin type 2 (AT2) receptor agonist, compound 21 (C21), provides neuroprotection and enhances recovery in rodent stroke models yet the mechanism involved is not known. Moreover, C21 treatment is associated with an anti-inflammatory response. Here we tested the hypothesis that C21 mediates neuroprotection by upregulating the neuroprotective and anti-inflammatory cytokine, interleukin (IL)−10. Methods Wistar rats were subjected to 3 h-middle cerebral artery suture occlusion and treated at reperfusion with C21 (0.03 mg/kg)±IL-10 neutralizing antibody (0.1 mg/kg) both given i.p. Infarct size, behavioral outcomes, and molecular analysis were performed at 24 h post-injury. Primary rat neurons were used to test the direct neuroprotective effect of C21 in vitro. Results C21 treatment reduced infarct size, improved functional outcome and decreased the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF-α) in the ischemic hemisphere compared to saline. Anti-IL-10 co-treatment blocked the C21-induced reduction in infarct size and inflammation, and the improvement in behavioral outcome. In vitro, C21 treatment increased neuron survival and reduced cell apoptosis after oxygen glucose deprivation (OGD) and OGD/reoxygenation. These effects were mediated through AT2R stimulation. Conclusion C21 provides direct neuroprotection as well as indirect protection through IL-10.

AB - Introduction We and others have shown that the angiotensin type 2 (AT2) receptor agonist, compound 21 (C21), provides neuroprotection and enhances recovery in rodent stroke models yet the mechanism involved is not known. Moreover, C21 treatment is associated with an anti-inflammatory response. Here we tested the hypothesis that C21 mediates neuroprotection by upregulating the neuroprotective and anti-inflammatory cytokine, interleukin (IL)−10. Methods Wistar rats were subjected to 3 h-middle cerebral artery suture occlusion and treated at reperfusion with C21 (0.03 mg/kg)±IL-10 neutralizing antibody (0.1 mg/kg) both given i.p. Infarct size, behavioral outcomes, and molecular analysis were performed at 24 h post-injury. Primary rat neurons were used to test the direct neuroprotective effect of C21 in vitro. Results C21 treatment reduced infarct size, improved functional outcome and decreased the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF-α) in the ischemic hemisphere compared to saline. Anti-IL-10 co-treatment blocked the C21-induced reduction in infarct size and inflammation, and the improvement in behavioral outcome. In vitro, C21 treatment increased neuron survival and reduced cell apoptosis after oxygen glucose deprivation (OGD) and OGD/reoxygenation. These effects were mediated through AT2R stimulation. Conclusion C21 provides direct neuroprotection as well as indirect protection through IL-10.

KW - And Interleukin 10

KW - Angiotensin Type 2 Receptor

KW - Compound 21

KW - Neuroprotection

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85012940606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012940606&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2017.02.016

DO - 10.1016/j.ejphar.2017.02.016

M3 - Article

C2 - 28192099

AN - SCOPUS:85012940606

VL - 799

SP - 128

EP - 134

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -